Takara Bio Europe AB & PanCryos Announce Agreement to Enable Development of Cell-Based Therapy for Diabetes
Takara Bio Europe AB & PanCryos Announce Agreement to Enable Development of Cell-Based Therapy for Diabetes
26 May 2021Science
Takara Bio Europe AB (TBEAB) and PanCryos are pleased to announce that they have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucose-responsive beta cells and is one of several customers in TBEAB’s new out-licensing program, which enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications. Jacqueline Ameri, CEO of PanCryos said, We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will put us in a position